This content is not available in your region

J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -study

Access to the comments Comments
By Reuters
J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows
J&J, Sinopharm, Sputnik V shots weaker against Omicron, study shows   -   Copyright  Thomson Reuters 2021   -  

<div> <p> – <span class="caps">COVID</span>-19 vaccines from U.S. drugmaker Johnson & Johnson and China’s Sinopharm as well as Russia’s Sputnik V shot had no neutralizing activity against the Omicron variant, according to a study which has not yet been peer reviewed.</p> <p>The study – conducted by Humabs Biomed SA, a unit of Vir Biotechnology, and the University of Washington, among others – compared the activity of some widely-used <span class="caps">COVID</span>-19 vaccines and treatments against Omicron and against the original virus strain first detected in China. </p> <p>Vaccines from Moderna, AstraZeneca, Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly reduced when compared with the original strain, the study found.</p> <p>It also found the decrease was less pronounced for vaccinated individuals who were previously infected. </p> <p>Russia’s Gamaleya Center issed a statement saying that the Sputnik V shot was tested “deliberately using serum samples that are not representative” and thus, conclusions about its effectiveness against the Omicron variant based on the study could not be made. </p> <p>The Russian Direct Investment Fund said on Friday that the vaccine induces a “robust neutralizing” antibody response to the Omicron variant, citing a preliminary lab study by the Gamaleya Center.</p> <p>Humabs Biomed’s study also found that while the effectiveness of GlaxoSmithKline and Vir Biotech’s <span class="caps">COVID</span>-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.</p> <p>The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.</p> <p>In a real-world study published this week, it was seen that Pfizer-BioNTech’s <span class="caps">COVID</span>-19 vaccine has been less effective in South Africa at keeping people infected with the virus out of hospital since the Omicron variant emerged last month.</p> <p/> </div>